The Pharmacoeconomics of Oral and Self-Administered Cancer Treatments

Oral and patient-administered forms of chemotherapy have come a long way since the 1950s, when mercaptopurine and methotrexate were first approved by the U.S. Food and Drug Administration (FDA). Several oral anticancer medications (OAMs)...

Online Exclusives

Hemophilia Drug Receives Priority Review From FDA

The U.S. Food and Drug Administration (FDA) has granted priority review to Roche’s biosimilar for emicizumab, a monoclonal antibody to treat children and adults...

Layoffs Suggest Deeper Problems Within Watson Health

Watson Health, an IBM project, cut staff from recently acquired data companies Explorys, Phytel, and Truven Health Analytics in an extensive round of layoffs...

News

From the Blood Journals

WIB_icon

Study Finds Thromboembolism Is a Frequent Complication of ALL Treatment

Adolescents and adults with acute lymphocytic leukemia (ALL) are at a “markedly” increased risk for developing thromboembolism (TE), even when treated according to the...
WIB_icon

Children With Ambiguous Leukemia Fare Better With Lymphoid-Directed Treatment

While most patients with acute leukemia have disease with a lymphoid or myeloid linage, 2 to 5 percent have “acute leukemia of ambiguous lineage”...

Multimedia

video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
video

Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia

Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...
video

Does Blinatumomab Affect CAR T-Cell Therapy Response?

In new data from ZUMA-3, patients with acute lymphocytic leukemia responded to CD19-targeting CAR T-cell therapy, regardless of prior CD19-targeting therapy with blinatumomab. Bijal...

On Location

Axicabtagene Ciloleucel Moves to Acute Lymphocytic Leukemia

Axicabtagene ciloleucel, which in October 2017 became the first chimeric antigen receptor (CAR) T-cell therapy...

Acalabrutinib Induces Durable Response in Patients With Waldenström Macroglobulinemia

In a phase II study of patients with Waldenström macroglobulinemia (WM), treatment with the highly...

Moxetumomab Pasudotox: An Alternative to Chemotherapy in Relapsed/Refractory Hairy Cell Leukemia

In a pivotal phase III clinical trial of moxetumomab pasudotox in patients with relapsed/refractory hairy...

Chemotherapy-Free Combination Shows Efficacy in Untreated Follicular Lymphoma

The randomized, global, phase III RELEVANCE trial showed that a regimen of lenalidomide and rituximab...

Positive Results With Ivosidenib in Patients With High-Risk, Previously Treated AML

Treatment with ivosidenib, a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor, led to durable remissions among...

Venetoclax, Carfilzomib, Dexamethasone Combo Appears Well Tolerated in Relapsed/Refractory MM

In an ongoing phase II study, the addition of the BCL2 inhibitor venetoclax to the...

Latest Headlines

Advertisement

ASH Directions

ASH Choosing Wisely Item Makes the ABIM Top 12, Celebrating World Sickle Cell Day,...

ASH Choosing Wisely Recommendation Makes the ABIM Top 12 The Choosing Wisely® campaign, an initiative of the American Board of Internal Medicine (ABIM) Foundation, encourages clinicians...

ASH Announces Partnership to Foster Genomic Research, The Hematologist Debuts Two New Departments, and...

ASH Programs Promoting Advocacy and Translational Research Now Accepting Nominations Advocacy Leadership Institute The American Society of Hematology (ASH) is now accepting nominations for...

Sign up for our
eNewsletter!

ACS Grants $47 Million in Funding, Stand Up to Cancer Announces Innovation Awards, and...

Lawrence B. Gardner, MD, an assistant professor of medicine and pharmacology at New York University (NYU) Langone Health, died on March 27 at age...

Stand Up To Cancer Funds AI Research, Damon Runyon Cancer Research Foundation Research Fellows...

Remembering Barry Paw (1961-2017) Barry Paw, MD, PhD, a principal investigator and pediatric oncologist at Brigham and Women’s Hospital and Dana-Farber/Boston Children’s Cancer and Blood...

Remembering Ihor R. Lemischka and Günter Blobel, Feinstein Institute Researcher Awarded NIH Grant, and...

Remembering Ihor R. Lemischka (1953-2017) Ihor R. Lemischka, PhD, a pioneer in the fields of hematopoiesis and pluripotent cell biology, died on December 17, 2017.Dr....

The Pharmacoeconomics of Oral and Self-Administered Cancer Treatments

Oral and patient-administered forms of chemotherapy have come a long way since the 1950s, when mercaptopurine and methotrexate were first approved by the U.S....

Genetic Testing: Ready, Set … Actionable?

In June 2000, President Bill Clinton announced that the international Human Genome Project and Celera Genomics had completed the initial sequencing of the human...

Exploring the Boundaries of Drug Importation

Importing pharmaceuticals from other countries to access lower-cost medicines is still a relatively murky issue. Hematologist Kenneth R. Adler, MD, of Summit Medical Group MD...